These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24635908)

  • 1. Cost effectiveness of caspofungin vs. voriconazole for empiric therapy in Turkey.
    Turner SJ; Senol E; Kara A; Al-Badriyeh D; Dinleyici EC; Kong DC
    Mycoses; 2014 Aug; 57(8):489-96. PubMed ID: 24635908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey.
    Turner SJ; Senol E; Kara A; Al-Badriyeh D; Kong DC; Dinleyici EC
    Int J Antimicrob Agents; 2013 Sep; 42(3):276-80. PubMed ID: 23830892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey.
    Turner SJ; Senol E; Kara A; Al-Badriyeh D; Dinleyici EC; Kong DC
    BMC Infect Dis; 2013 Nov; 13():560. PubMed ID: 24279677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
    Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
    Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
    Stam WB; Aversa F; Kumar RN; Jansen JP
    Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
    Selleslag D; Vogelaers D; Marbaix S
    Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
    Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
    Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
    Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
    Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
    Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.
    Mistro S; Rosa L; Gomes B; Miranda L; Badaró R
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):465-73. PubMed ID: 27322156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
    Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
    Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
    Agarwal MB; Rathi SA; Ratho N; Subramanian R
    J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: A systematic review and meta-analysis.
    Yamashita C; Takesue Y; Matsumoto K; Ikegame K; Enoki Y; Uchino M; Miyazaki T; Izumikawa K; Takada T; Okinaka K; Ueda T; Miyazaki Y; Mayumi T
    J Infect Chemother; 2020 Jun; 26(6):596-603. PubMed ID: 32171659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.